Results 81 to 90 of about 150,085 (313)

Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) [PDF]

, 2011
<p>Background: Venous thromboembolic events (VTE), including deep venous thrombosis and pulmonary embolism, are common in older age. It has been suggested that statins might reduce the risk of VTE however positive results from studies of middle ...
Frölich Marijke, Marijke Frölich, Frölich, Margaret, Brown, E.A., Jukema J Wouter, Anton JM de Craen, Ford Ian, Ian Ford, Frolich, M., E Ann Brown, Slagboom, P. Eline, Freeman Dilys J, Greer Ian A, Ann Rumley, Rumley, A., David J Stott, Tobias, E.S., Greer, I.A., Slagboom P Eline, Ian A Greer, Gordon DO Lowe, Stott David J, P Eline Slagboom, Greer, Ian A., Craen, A.J.M. de, de Craen, Anton J.M., Rumley, Ann, Allan Gaw, Freeman, D.J., Tobias, Edward S., Naveed Sattar, Ford, Ian, Brown E Ann, Gaw, A., Jukema, J.W., Lowe, G.D.O., Dilys J Freeman, Freeman, Dilys J., Sattar, N., Jukema, J. Wouter, Lowe, Gordon D.O., Ford, I., Robertson, Michele, Sattar Naveed, Slagboom, P.E., Robertson, M., de Craen Anton JM, Robertson Michele, Brown, E. Ann, Michele Robertson, Tobias Edward S, J Wouter Jukema, Sattar, Naveed, Stott, David J., Gaw, Allan, Rumley Ann, Lowe Gordon DO, Edward S Tobias, Stott, D.J., Gaw Allan   +59 more
core   +1 more source

Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó, Laurel Woodridge, Sagrario Corrales, Juan Rafael Muñoz‐Castañeda, Ana Isabel Torralbo, Anisur Rahman, Filipa Farinha, Rafaela Ortega Castro, Pedro Segui, Ismael Sanchez‐Pareja, Laura Muñoz‐Barrera, Christian Merlo, Desiree Ruiz‐Vilchez, M. Carmen Ábalos‐Aguilera, Pilar Font, Nuria Barbarroja Puerto, PRECISESADS Clinical Consortium, Lorenzo Beretta, Barbara Vigone, Jacques‐Olivier Pers, Alain Saraux, Valérie Devauchelle‐Pensec, Divi Cornec, Sandrine Jousse‐Joulin, Bernard Lauwerys, Julie Ducreux, Anne‐Lise Maudoux, Carlos Vasconcelos, Ana Tavares, Esmeralda Neves, Raquel Faria, Mariana Brandão, Ana Campar, António Marinho, Fátima Farinha, Isabel Almeida, Miguel Angel Gonzalez‐Gay Mantecón, Ricardo Blanco Alonso, Alfonso Corrales Martínez, Ricard Cervera, Ignasi Rodríguez‐Pintó, Gerard Espinosa, Rik Lories, Ellen De Langhe, Nicolas Hunzelmann, Doreen Belz, Torsten Witte, Niklas Baerlecken, Georg Stummvoll, Michael Zauner, Michaela Lehner, Eduardo Collantes, Ma Carmen Castro‐Villegas, Norberto Ortego, María Concepción Fernández Roldán, Enrique Raya, Inmaculada Jiménez Moleón, Enrique de Ramon, Isabel Díaz Quintero, Pier Luigi Meroni, Maria Gerosa, Tommaso Schioppo, Carolina Artusi, Carlo Chizzolini, Aleksandra Zuber, Donatienne Wynar, Laszló Kovács, Attila Balog, Magdolna Deák, Márta Bocskai, Sonja Dulic, Gabriella Kádár, Falk Hiepe, Velia Gerl, Silvia Thiel, Manuel Rodriguez Maresca, Antonio López‐Berrio, Rocío Aguilar‐Quesada, Héctor Navarro‐Linares, Marta Alarcón‐Riquelme, Alejandro Escudero‐Contreras, M. Ángeles Aguirre‐Zamorano, Carlos Perez‐Sanchez, Elizabeth C. Jury, Chary Lopez‐Pedrera   +84 more
wiley   +1 more source

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

Hepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo, Gonzalo Crespo, Dyanna Gregory, Jasmine Sinha, Jiaheng Xie, Min Zhang, John Magee, Pranab Barman, Yuval A. Patel, Aaron Schluger, Kara Walters, Scott Biggins, Natalia Filipek, Giuseppe Cullaro, Randi Wong, Jennifer C. Lai, Gabriel J. Perreault, Elizabeth C. Verna, Pratima Sharma, Lisa B. VanWagner   +19 more
wiley   +1 more source

Cholesterol suppresses antimicrobial effect of statins [PDF]

Iranian Journal of Basic Medical Sciences, 2015
Objective(s):Isoprenoid biosynthesis is a key metabolic pathway to produce a wide variety of biomolecules such as cholesterol and carotenoids, which target cell membranes.
Mohammad Reza Haeri, Kenneth White, Mohammad Qharebeglou, Malek Moein Ansar   +3 more
doaj  

Effect of Statin Therapy on Outcomes of Patients With Acute Ischemic Stroke and Atrial Fibrillation

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background There is insufficient evidence on the effect of statins, particularly high‐intensity statins, in patients with acute ischemic stroke and atrial fibrillation.
Kang‐Ho Choi, Woo‐Keun Seo, Man‐Seok Park, Joon‐Tae Kim, Jong‐Won Chung, Oh Young Bang, Gyeong‐Moon Kim, Tae‐Jin Song, Bum Joon Kim, Sung Hyuk Heo, Jin‐Man Jung, Kyung‐Mi Oh, Chi Kyung Kim, Sungwook Yu, Kwang‐Yeol Park, Jeong‐Min Kim, Jong‐Ho Park, Jay Chol Choi, Yang‐Ha Hwang, Yong‐Jae Kim   +19 more
doaj   +1 more source

Investigating the effects of statins on ischemic heart disease allowing for effects on body mass index: a Mendelian randomization study

Scientific Reports, 2022
Despite effective lipid reduction and corresponding benefits for cardiovascular disease prevention and treatment, statins have pleiotropic effects potentially increasing the risk of ischemic heart disease (IHD), particularly by increasing body mass index
Shun Li, C. M. Schooling
doaj   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Statins in the Cause and Prevention of Cancer: Confounding by Indication and Mediation by Rhabdomyolysis and Phosphate Toxicity

Journal of Cardiovascular Development and Disease
Statins are drugs used in cardiovascular pharmacotherapy to decrease hypercholesterolemia and lower the risk of atherosclerosis. Statins also increase the risk of rhabdomyolysis, which is often minimized in comparison with large relative risk reductions ...
Ronald B. Brown
doaj   +1 more source

Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.

PLoS ONE, 2008
BackgroundThe 3-hydroxy-3-methylglutaryl CoA reductase inhibitors (also called statins) exert proven beneficial effects on cardiovascular diseases. Recent data suggest a protective role for Transforming Growth Factor-beta (TGF-beta) in atherosclerosis by
Juan Rodríguez-Vita, Eva Sánchez-Galán, Beatriz Santamaría, Elsa Sánchez-López, Raquel Rodrigues-Díez, Luís Miguel Blanco-Colio, Jesús Egido, Alberto Ortiz, Marta Ruiz-Ortega, Marta Ruiz-Ortega   +9 more
doaj   +1 more source

Association between statin use, the vaginal microbiome, and Gardnerella vaginalis vaginolysin-mediated cytotoxicity. [PDF]

PLoS ONE, 2017
BACKGROUND:Bacterial vaginosis (BV) is the leading dysbiosis of the vaginal microbiome. The pathways leading towards the development of BV are not well understood. Gardnerella vaginalis is frequently associated with BV. G.
Abdallah A Abdelmaksoud, Philippe H Girerd, Erin M Garcia, J Paul Brooks, Lauren M Leftwich, Nihar U Sheth, Steven P Bradley, Myrna G Serrano, Jennifer M Fettweis, Bernice Huang, Jerome F Strauss, Gregory A Buck, Kimberly K Jefferson   +12 more
doaj   +1 more source